PharmAware Blog

11/11/2010

Roche fined for breaching promotion code

Filed under: International News — admin @ 12:48 pm

An Australian subsidiary of Roche has been fined £124,200 for offering a regional public health organisation funding for a nursing position in exchange for doctors in the region prescribing its hepatitis drug Pegasys.

BMJ 2010, 341, c6232

GSK agrees to pay fine for badly made drugs

Filed under: International News — admin @ 12:46 pm

GSK is to pay $750m to settle cirimal and civil complaints that the company had for year knowingly sold adulterated formulations of four drugs it produced in Puerto Rico.

Experts warn of rationing by GPs under new drug scheme

Filed under: UK News — admin @ 12:44 pm

Andrew Lansley, health secretary, has repearted stated his intention of moving the NHS to a value based pricing for drugs in the NHS. This means the government will negotiate prices with the pharmaceutical companies according to the therapeutic benefits they will bring to patients. However, this means that the role of NICE in ruling whether drugs should be made available to patients on the NHS will be reductant. In addition, this move will lead to GPs having to take on the role of rationing drugs and is likely to lead to a postcode lottery.

BMJ 2010, 341, c6240

01/11/2010

Dollars for Docs - Drug companies accursed of using unsuitable doctors for promotion

Filed under: International News — admin @ 03:24 pm

The drug companies pay hundreds of doctors who have been disciplined for ethical breaches or had their medical licences revolked as speakers and consultants says a ProPublica report. The reporters created a searchable database  of payments to doctors since 2009. The report can be found at http://www.propublica.org/article/profiles-of-the-top-earners-in-dollar-for-docs and the database at http://projects.propublica.org/docdollars/.

BMJ 2010; 341:c6026

27/10/2010

European Medicines Agency tightens rules on experts’ interaction with drug industry

Filed under: International News — admin @ 10:36 am

The EMA has launched much stricter rules for its experts’ interactions with the drug industry. The agency’s new guidance on conflicts of interest says people who have interests in a company will have their work with the agency restricted. The policy is due to come into efect next year.

BMJ 2010, 341, c5902

Government drops plans for generic substitution

Filed under: UK News — admin @ 10:32 am

The coalition governement has dropped plans to introduce the automatic substitution of generic drugs in primary care in England.

BMJ 2010, 341, c5780

US drug company executives could face criminal charges

Filed under: International News — admin @ 10:30 am

Executives of drug companies could face criminal charges if companies promote the off-label use of drugs, says an attorney for the US Food and Drug Administration. This aims to move away from fines to companies which does not currently seem to act as a deterrent for companies.

BMJ 2010, 341, c5808

18/10/2010

Teco granted licence to sell Viagra

Filed under: UK News — admin @ 10:44 am

Tesco has been granted permission to sell sildenafil (Viagra) in 300 pharmacies in its supermarkets without the need for a prescription from a GP. The Medicines and Healthcare Regulatory Agency confirmed that sildenafil remains prescription only and that Tesco has been granted permission to dispense the drug uder a special licence called patient group direction. These licences are granted in situations where they offer an advantage to the care of patients without compromising their safety and where they provide an opportunity for general health screening.

BMJ 2010, 341, c5294

New rules allow EU patients to report drug concerns directly

Filed under: International News — admin @ 10:39 am

On September 22, the European parliament agreed new legislation on pharmacovigilence. Under this new system, national web portals will be established to provide the public with information on medicinal products and any known side effects. The portals will contain assessment reports, summaries of product characteristics and information leaflets. They will be linked to the EU’s EudraVigilance database.

BMJ 2010, 341, c5344

Boehringer halts development of libido drug for women

Filed under: International News — admin @ 10:29 am

Boehringer announce that it is withdrawing its drug, flibanserin, for increasing femal sexual desire, from development. The company made the announcement after negative reviews from the US Food and Drug Administration.

BMJ 201, 341, c5701

« Previous PageNext Page »

Powered by WordPress